Do analysts prefer PHXM or MIRA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, PHXM or MIRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is PHXM or MIRA more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A MIRA Pharmaceuticals N/A -140.82% -135.01%

Which has better valuation and earnings, PHXM or GRDX?

PHAXIAM Therapeutics has higher earnings, but lower revenue than Entero Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Entero Therapeutics $74.46K 470.88 -$6.39M -$1.88 N/A

Is PHXM or GRDX more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Entero Therapeutics N/A -49.81% -11.02%

Do analysts prefer PHXM or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PHXM or ZYBT?

PHAXIAM Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A Zhengye Biotechnology $16.64M 2.36 -$9.98M N/A N/A

Is PHXM or ZYBT more profitable?

Company Net Margins Return on Equity Return on Assets PHAXIAM Therapeutics N/A N/A N/A Zhengye Biotechnology N/A N/A N/A

Which has stronger valuation and earnings, IXHL or PHXM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incannex Healthcare N/A N/A -$46.88M -$1.55 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is IXHL or PHXM more profitable?

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity. Company Net Margins Return on Equity Return on Assets Incannex Healthcare N/A -81.01% -76.11% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate PHXM or RNXT?

RenovoRx has a consensus price target of $8.50, indicating a potential upside of 907.35%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than PHAXIAM Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 RenovoRx 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has preferable earnings and valuation, PHXM or RNXT?

PHAXIAM Therapeutics has higher earnings, but lower revenue than RenovoRx. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PHAXIAM Therapeutics N/A N/A -$240K N/A N/A RenovoRx $1.49M 25.56 -$11.17M -$0.33 N/A

PHAXIAM Therapeutics (PHXM) Competitors

$3.10 0.00 (0.00%)

As of 06/12/2026

Compare

PHXM vs. MIRA, GRDX, ZYBT, IXHL, and RNXT

Should you buy PHAXIAM Therapeutics stock or one of its competitors? MarketBeat compares PHAXIAM Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PHAXIAM Therapeutics include MIRA Pharmaceuticals (MIRA), Entero Therapeutics (GRDX), Zhengye Biotechnology (ZYBT), Incannex Healthcare (IXHL), and RenovoRx (RNXT). These companies are all part of the "pharmaceutical products" industry.

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

PHAXIAM Therapeutics (NASDAQ:PHXM) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

PHAXIAM Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

PHAXIAM Therapeutics has a beta of 2.35, indicating that its stock price is 135% more volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for PHAXIAM Therapeutics. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat PHAXIAM Therapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
MIRA Pharmaceuticals	Positive

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

MIRA Pharmaceuticals beats PHAXIAM Therapeutics on 6 of the 10 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Entero Therapeutics?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

PHAXIAM Therapeutics' return on equity of 0.00% beat Entero Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Entero Therapeutics	N/A	-49.81%	-11.02%

In the previous week, Entero Therapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Entero Therapeutics and 0 mentions for PHAXIAM Therapeutics. Entero Therapeutics' average media sentiment score of 1.87 beat PHAXIAM Therapeutics' score of 0.00 indicating that Entero Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Entero Therapeutics	Very Positive

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by company insiders. Comparatively, 0.8% of Entero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

PHAXIAM Therapeutics has higher earnings, but lower revenue than Entero Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Entero Therapeutics	$74.46K	470.88	-$6.39M	-$1.88	N/A

Summary

PHAXIAM Therapeutics beats Entero Therapeutics on 5 of the 9 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Zhengye Biotechnology?

PHAXIAM Therapeutics (NASDAQ:PHXM) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
Zhengye Biotechnology	N/A	N/A	N/A

In the previous week, Zhengye Biotechnology had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for Zhengye Biotechnology and 0 mentions for PHAXIAM Therapeutics. Zhengye Biotechnology's average media sentiment score of 0.94 beat PHAXIAM Therapeutics' score of 0.00 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
Zhengye Biotechnology	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

PHAXIAM Therapeutics has a beta of 2.35, suggesting that its share price is 135% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.4, suggesting that its share price is 340% less volatile than the broader market.

PHAXIAM Therapeutics has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
Zhengye Biotechnology	$16.64M	2.36	-$9.98M	N/A	N/A

0.4% of PHAXIAM Therapeutics shares are held by institutional investors. 1.9% of PHAXIAM Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

PHAXIAM Therapeutics and Zhengye Biotechnology tied by winning 4 of the 8 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Incannex Healthcare had 8 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 8 mentions for Incannex Healthcare and 0 mentions for PHAXIAM Therapeutics. Incannex Healthcare's average media sentiment score of 0.77 beat PHAXIAM Therapeutics' score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Positive
PHAXIAM Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	N/A	N/A	-$46.88M	-$1.55	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

PHAXIAM Therapeutics' return on equity of 0.00% beat Incannex Healthcare's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-81.01%	-76.11%
PHAXIAM Therapeutics	N/A	N/A	N/A

Incannex Healthcare currently has a consensus price target of $18.00, indicating a potential upside of 369.97%. Given Incannex Healthcare's stronger consensus rating and higher probable upside, equities research analysts plainly believe Incannex Healthcare is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Incannex Healthcare has a beta of 7, indicating that its share price is 600% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Incannex Healthcare beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks.

How does PHAXIAM Therapeutics compare to RenovoRx?

PHAXIAM Therapeutics (NASDAQ:PHXM) and RenovoRx (NASDAQ:RNXT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

PHAXIAM Therapeutics has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market. Comparatively, RenovoRx has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

RenovoRx has a consensus price target of $8.50, indicating a potential upside of 907.35%. Given RenovoRx's stronger consensus rating and higher possible upside, analysts plainly believe RenovoRx is more favorable than PHAXIAM Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PHAXIAM Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
RenovoRx	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of RenovoRx shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Comparatively, 9.1% of RenovoRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, RenovoRx had 2 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 2 mentions for RenovoRx and 0 mentions for PHAXIAM Therapeutics. RenovoRx's average media sentiment score of 0.93 beat PHAXIAM Therapeutics' score of 0.00 indicating that RenovoRx is being referred to more favorably in the news media.

Company	Overall Sentiment
PHAXIAM Therapeutics	Neutral
RenovoRx	Positive

PHAXIAM Therapeutics has higher earnings, but lower revenue than RenovoRx.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A
RenovoRx	$1.49M	25.56	-$11.17M	-$0.33	N/A

PHAXIAM Therapeutics has a net margin of 0.00% compared to RenovoRx's net margin of -823.98%. PHAXIAM Therapeutics' return on equity of 0.00% beat RenovoRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PHAXIAM Therapeutics	N/A	N/A	N/A
RenovoRx	-823.98%	-135.03%	-101.92%

Summary

RenovoRx beats PHAXIAM Therapeutics on 9 of the 14 factors compared between the two stocks.

Get PHAXIAM Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHXM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHXM vs. The Competition

Export

Metric	PHAXIAM Therapeutics	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.58M	$445.83M	$6.52B	$12.05B
Dividend Yield	N/A	3.88%	2.67%	5.66%
P/E Ratio	N/A	3.18	24.00	24.42
Price / Sales	N/A	6,505.70	533.77	123.88
Price / Cash	N/A	13.13	27.48	37.92
Price / Book	0.39	86.91	10.55	6.82
Net Income	-$240K	-$96.07M	$3.57B	$337.56M
7 Day Performance	N/A	0.03%	0.59%	1.16%
1 Month Performance	N/A	-0.34%	1.55%	3.16%
1 Year Performance	N/A	56.16%	25.41%	30.60%

PHAXIAM Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49
MIRA MIRA Pharmaceuticals	0.9624 of 5 stars	$0.98 -2.3%	N/A	-22.3%	$42.02M	N/A	N/A	2
GRDX Entero Therapeutics	1.0595 of 5 stars	$6.37 +2.4%	N/A	N/A	$41.38M	$40K	N/A	9	Positive News Gap Down
ZYBT Zhengye Biotechnology	0.9184 of 5 stars	$0.89 +3.1%	N/A	-86.9%	$40.95M	$16.64M	N/A	278
IXHL Incannex Healthcare	1.9577 of 5 stars	$3.67 +7.9%	$18.00 +390.5%	-38.1%	$40.68M	$90K	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHXM) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. MIRA, GRDX, ZYBT, IXHL, and RNXT

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does PHAXIAM Therapeutics compare to Entero Therapeutics?

Summary

How does PHAXIAM Therapeutics compare to Zhengye Biotechnology?

Summary

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Summary

How does PHAXIAM Therapeutics compare to RenovoRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PHAXIAM Therapeutics (PHXM) Competitors

PHXM vs. MIRA, GRDX, ZYBT, IXHL, and RNXT

How does PHAXIAM Therapeutics compare to MIRA Pharmaceuticals?

Is PHXM or MIRA more profitable?

Which has more risk and volatility, PHXM or MIRA?

Does the media refer more to PHXM or MIRA?

Do insiders & institutionals have more ownership in PHXM or MIRA?

Which has preferable earnings and valuation, PHXM or MIRA?

Do analysts prefer PHXM or MIRA?

Summary

How does PHAXIAM Therapeutics compare to Entero Therapeutics?

Is PHXM or GRDX more profitable?

Does the media favor PHXM or GRDX?

Do institutionals and insiders have more ownership in PHXM or GRDX?

Which has more volatility and risk, PHXM or GRDX?

Which has better valuation and earnings, PHXM or GRDX?

Summary

How does PHAXIAM Therapeutics compare to Zhengye Biotechnology?

Is PHXM or ZYBT more profitable?

Does the media refer more to PHXM or ZYBT?

Do analysts prefer PHXM or ZYBT?

Which has more risk and volatility, PHXM or ZYBT?

Which has higher valuation and earnings, PHXM or ZYBT?

Do institutionals & insiders believe in PHXM or ZYBT?

Summary

How does PHAXIAM Therapeutics compare to Incannex Healthcare?

Does the media prefer IXHL or PHXM?

Which has stronger valuation and earnings, IXHL or PHXM?

Is IXHL or PHXM more profitable?

Do analysts recommend IXHL or PHXM?

Which has more volatility & risk, IXHL or PHXM?

Do institutionals and insiders believe in IXHL or PHXM?

Summary

How does PHAXIAM Therapeutics compare to RenovoRx?

Which has more risk and volatility, PHXM or RNXT?

Do analysts rate PHXM or RNXT?

Do institutionals and insiders believe in PHXM or RNXT?

Does the media refer more to PHXM or RNXT?

Which has preferable earnings and valuation, PHXM or RNXT?

Is PHXM or RNXT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHXM vs. The Competition

PHAXIAM Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools